Abstract
Background and Aims: Several epidemiological studies have shown that lipoprotein-associated phospholipase A2 (Lp-PLA2) is an independent risk factor for coronary artery disease. Lp-PLA2 is secreted by proinflammatory cells and is highly expressed in the atherosclerotically changed arterial wall. Recently, lower activity of Lp-PLA2 has been observed in plasmas from everolimus-treated patients. In vitro studies revealed reduced Lp-PLA2 expression in hepatocytes and macrophages pre-exposed to everolimus, while antiatherosclerotic activity of everolimus has been shown in animal models of disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
